Gilead Sciences, Inc. (GILD)
NASDAQ • Healthcare
November 6, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Gilead Sciences, Inc. keeps $29 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Gilead Sciences topped revenue expectations on preliminary second fiscal quarter of 2026 results reported Aug. 4, as revenue rose 10.2% to about $7.8 billion from $7.08 billion a year ago and beat the about $7.4 billion consensus by 5.5%. Total product sales, the largest segment, rose 5.0% to about $7.0 billion, while the U.S. remained the biggest geographic concentration at about $4.9 billion, up 5.5%. Gross profit came in at roughly $6.2 billion and gross margin held near 80%, with operating cash flow of $3.57 billion and $1.04 billion paid in dividends. Consensus for the next period calls for EPS of $2.16 on revenue of $7.76 billion.
About Gilead Sciences, Inc.
Gilead Sciences, Inc. discovers, develops, and commercializes medicines for critical health needs and trades on the NASDAQ as GILD. The biopharmaceutical company sits in healthcare, with FY2025 revenue of $29.4 billion, and its portfolio spans antiviral therapies, oncology and cell therapy products, and specialty cardiovascular treatments.
Today's Snapshot
The day ended with GILD slightly lower at 166.89, in line with a flat sector. Gilead Sciences faced regulatory hurdles as new evidence emerged for Livdelzi, its liver-disease drug.
Trading Volume
Below 10d avg (7.8M)
5.6M
vs S&P 500 Today
Underperforming Market
-0.81%
Updated: November 6, 2026 at 21:19 UTC
GILD Headlines
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$141.62 - $165.85Buy
- RSI (14)60.24Neutral
- Stochastic %K (14, 3, 3)73.31Neutral
- MACD Level (12, 26)5.29Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.